Federal Register / Vol. 60, No. 79 / Tuesday, April 25, 1995 / Notices 20259

Thailand with respect to three like

product categories classified under 12

Harmonized Tariff Schedule (HTS) item

numbers.

EFFECTIVE DATE: April 25, 1995.

FOR FURTHER INFORMATION CONTACT:

Jacqueline Wallace or Steve Presing,

Office of Agreements Compliance,

Import Administration, International

Trade Administration, U.S. Department

of Commerce, 14th Street and

Constitution Avenue, NW., Washington,

DC 20230; telephone: (202) 482–1394 or

(202) 482–0194.

SUPPLEMENTARY INFORMATION:

Background

On March 1, 1994, the Department

published in the Federal Register

notification of its intent to terminate the

suspended investigation covering

Certain Textile Mill Products from

Thailand and invited interested parties

to comment (59 FR 9727, dated March

1, 1994). On March 31, 1994, the

Department received timely objections

to the intent to terminate the suspended

investigation from the Amalgamated

Clothing and Textile Workers Union

(ACTWU); American Textile

Manufacturers Institute, Inc. (ATMI);

Certain Individual Producers of ATMI;

American Yarn Spinners Association

(AYSA); and Certain Individual

Producers of AYSA.

On April 22, 1994, the Royal Thai

Government (RTG) and Thai Textile

Manufacturers Association (TTMA),

challenged the interested party status of

those parties who objected to our intent

to terminate the suspended

investigation. As a result of the

objections received from the RTG and

TTMA, the Department requested

certifications demonstrating interested

party status from ACTWU, ATMI,

certain individual producers of ATMI,

AYSA, and certain individual producers

of AYSA in accordance with 19 CFR

355.2(i) (3), (4), and (5). Based on our

analysis of interested party status by

like product categories (See internal

recommendation from Roland

MacDonald to Joseph A. Spetrini dated

January 12, 1995, for a complete

analysis), we have determined that it is

appropriate to terminate the suspended

investigation with respect to the

following three like product categories

because the Department did not receive

certifications demonstrating interested

party status:

(1) Yarn of Man Made Fiber

Continuous Cellulosic

5401.20.0000

5406.20.0000

(2) Other Miscellaneous Categories

Wadding & Articles

5601.10.1000

5601.21.0010

5601.21.0090

Other Made-up Articles

6307.10.2005

6307.10.2015

6307.10.2020

6307.10.2027

6307.10.2028

6307.10.2030

(3) Wool Made-Ups and Miscellaneous

Floor Coverings

5703.10.0000

This notice is in accordance with 19

CFR 355.25(d)(4)(i).

Dated: April 18, 1995.

Joseph A. Spetrini,

Deputy Assistant Secretary for Compliance.

[FR Doc. 95–10166 Filed 4–24–95; 8:45 am]

BILLING CODE 3510–DS–M

DEPARTMENT OF DEFENSE

Department of the Army

Availability of Non-Exclusive,

Exclusive, or Partially Exclusive

Licensing of U.S. Patents Concerning

Anticonvulsant and Neuroprotective

Agents

AGENCY: U.S. Army Medical Research

and Materiel Command, Department of

the Army, DOD.

ACTION: Notice.

SUMMARY: In accordance with 37 CFR

404.6, announcement is made of the

availability for licensing of U.S. Patent

No. 5,258,386 entitled ‘‘(+)-3-

Substituted-N-Alkylmorphinans,

Synthesis and use as Anticonvulsant

and Neuroprotective Agents’’ and issued

on November 1, 1993, and U.S. Patent

No. 5,331,010 entitled ‘‘1-

Phenylalkanecarboxylic Acid

Derivatives as Anticonvulsant and

Neuroprotective Agents; and issued on

July 19, 1994. These patents have been

assigned to the United States

Government as represented by the

Secretary of the Army.

ADDRESSES: Commander, U.S. Army

Medical Research and Materiel

Command, ATTN: Staff Judge Advocate,

Fort Detrick, Frederick, Maryland

21702–5012.

FOR FURTHER INFORMATION CONTACT:

Mr. John F. Moran, Patent Attorney,

(301) 619–2065 or telefax (301) 619–

7714.

SUPPLEMENTARY INFORMATION: The

inventions represent discoveries that

members of certain classes of

compounds [(+)-3-substituted-Nalkylmorphinans and 1-

phenylalkanecarboxylic acids] possess

effective usefulness as nonaddictive

anticonvulsant and neuroprotective

agents. The 1-phenylalkanecarboxylic

acids include novel non-opiate

derivatives as well as previously

published species. Methods for

controlling convulsions in a variety of

pharmaceutical formulations and

modalities are described. In both

inventions, novel compounds which

possess these biological properties are

presented in a method or methods of

use for preventing, treating, or

controlling convulsions in mammals

having a need for such treatment. The

compounds do not lead to dependency,

have low toxicity, and provide effective

anticonvulsant or neuroprotective

treatment with little or no behavioral

detriment to the recipient.

Gregory D. Showalter,

Army Federal Register Liaison Officer.

[FR Doc. 95–10079 Filed 4–24–95; 8:45 am]

BILLING CODE 3710–08–M

Availability of Non-Exclusive,

Exclusive, or Partially Exclusive

Licensing of U.S. Patent Concerning a

Method for Lysing Thrombi

AGENCY: U.S. Army Medical Research

and Materiel Command, DOD.

ACTION: Notice.

SUMMARY: In accordance with 37 CFR

404.6, announcement is made of the

availability for licensing of U.S. Patent

No. 5,399,158, entitled ‘‘Method of

Lysing Thrombi’’, and issued on March

21, 1995. This patent has been assigned

to the United States Government as

represented by the Secretary of the

Army.

ADDRESSES: Commander, U.S. Army

Medical Research and Materiel

Command, ATTN: Command Judge

Advocate, Fort Detrick, Frederick,

Maryland 21702–5012.

FOR FURTHER INFORMATION CONTACT:

Mr. John F. Moran, Patent Attorney,

(301) 619–2065 or telefax (301) 619–

7714.

SUPPLEMENTARY INFORMATION: The

invention describes an improved

method for prevention or treatment of

thrombosis, including deep venous

thrombosis (DVT) and acute arterial

thrombosis, such as coronary artery

thrombosis, while avoiding damage to

the surrounding tissue. The method

includes the administration of

plasminogen activators in conjunction

with intermittent (pulse mode)

ultrasound and the imposition of a

fluid-containing barrier between the